Please assess the completion status of the following clinical trial:

Trial Title: Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
General~Inclusion Criteria:~1. Read, understand and sign the IRB- or IEC-approved ICF confirming his or her willingness to participate in this trial.~2. At least 18 years old.~3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~4. Adequate bone marrow function; normal renal and hepatic function, normal cardiac function.~5. Normal cardiac function in the opinion of the investigator and supported by LVEF 50% or greater on the screening echocardiogram (or MUGA), no significant abnormalities on the screening ECG (eg, left bundle branch block, III degree AV block, acute myocardial infarction, Wolff-Parkinson-White syndrome or QTc interval ≥ 450 msec) and no history of additional risk factors for torsades de pointes (eg, heart failure, hypokalemia or family history of Long QT Syndrome).~Exclusion Criteria:~1. Active secondary malignancy or history of other malignancy within the last two years except non-melanoma skin cancers or cervical carcinoma in situ.~2. History of significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure and/or myocardial infarction or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification.~3. Received any anticancer agent(s) within the past 3 weeks, including investigational agents, chemotherapy (6 weeks for nitrosoureas or mitomycin), immunotherapy, biologic or marketed or investigational tyrosine kinase inhibitors.~4. Received prior radiation therapy within the past 4 weeks or received irradiation of ≥ 25% of their bone marrow reserve.~5. Any serious, uncontrolled active infection that requires systemic treatment or known infection with HIV, HCV or HBV.~6. Symptomatic CNS metastases or lesions for which treatment is required.~Prostate Cancer~Inclusion Criteria:~1. Males with histologically confirmed adenocarcinoma of the prostate, which is now metastatic (e.g., any T, any N, M1a-c)based on bone scan, CT scan, or MRI scan. Demonstrated evidence of progressive disease despite androgen deprivation (androgen ablation or surgical castration), anti-androgen withdrawal and progression of disease after docetaxel-based therapy.~2. Demonstrated evidence of progressive disease despite androgen deprivation (androgen ablation or surgical castration), anti-androgen withdrawal and progression of disease after docetaxel-based therapy.~   • Greater than 25% increase in 3 consecutive tests (PSA 1 \< PSA 2 \< PSA 3), each PSA value separated by at least 1 week~3. Serum testosterone level ≤ 50 ng/dL post orchiectomy or while maintained on continuous or intermittent medical androgen suppression with a LHRH agonist or antagonist.~4. At least 4 weeks since prior flutamide, megestrol, ketoconazole, aminoglutethimide; and at least 6 weeks since prior bicalutamide or nilutamide.~5. Systemic corticosteroids discontinued within two weeks of dosing, except low dose regimens which may continue if unchanged~6. Strontium-89 or Samarium-153 must have been completed at least 8 weeks prior to the first dose of therapy and recovered from all treatment-related toxicities.~Exclusion Criteria:~1. Must not be receiving concurrent anti-androgen hormonal therapy for hormone refractory prostate cancer.~Non-Hodgkin's Lymphoma~Inclusion Criteria:~1. Histologically proven relapsed or refractory non-Hodgkin's lymphoma subjects for which there is no available standard therapy or therapy which may provide clinical benefit.~2. Measurable disease (at least 1 lesion ≥ 1.5 cm).~Exclusion Criteria:~1. Bulky disease by CT, defined as any single mass \>10 cm in its greatest diameter.~2. Systemic corticosteroids within 2 weeks, except low dose regimens which may continue if unchanged.~3. Received any radiopharmaceutical therapy within the past six weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues